Trade Setup
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer’s disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction.
Stocks found in the category TradersPro New Uptrend are low priced stocks priced between .20 and $7, with at least 50k shares of average shares trading per day. The stocks are starting new uptrends and have buy signals. These are high reward to risk stocks with the potential for very sharp moves. A stop should be maintained at the low of the most recent hold signal day. Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro. Trailing stops or letting the stock run until the next sell signal is also a sell strategy.
